Evommune's EVO756 failed to meet the primary end point in a phase 2b trial for chronic spontaneous urticaria, prompting the company to discontinue development for the indication while continuing studies in atopic dermatitis.
Shannon Heaning, Content Associate
Advertisement
Shannon Heaning is a content associate for Dermatology Times® and joined the MJH Life Sciences team in June 2026. She graduated summa cum laude from Loyola University Maryland with a Bachelor of Arts in sociology and earned the top GPA in her major. Before joining Dermatology Times®, Shannon gained experience in clinical research, patient advocacy, and health communications. She is particularly passionate about rare disease awareness and patient-centered storytelling. Outside of work, she enjoys reading, drawing, and spending time with her dogs.
You can reach her at: [email protected]
Articles by Shannon Heaning, Content Associate
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
3
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
4
FAQ: Everything Clinicians (and Their Patients) Want to Know About the Hair Loss Pipeline
5